EGFR and metastatic neoplasm: Independent prognostic marker.Associated with poorer overall survivalFull length and RHAMM variant 3 (RHAMM B) were overexpressed in metastatic tumors with RHAMM B being more expressed. HMMR B corresponded with worse prognosis.RHAMM B overexpression increased metastasis of BON1-TGL pancreatic neuroendocrine cells in vivo whilst full length RHAMM had no effect.EGFR activation was partially responsible for RHAMM B mediated metastasis in vivoHMMR knockout generates RHAMM (exon 8-16) deficient variant which promotes PDAC invasiveness.